FDA fast-tracks Nexavar for liver cancer
The FDA has fast-tracked an Onyx/Bayer drug on the fast-track for approval following Stage III trials. Nexavar looks like it'll be a competitor to Pfizer's Sutent — a drug which is showing promise in treating hithertofore untreatable renal cancer, and Wyeth's new experimental drug, Temsirolimus.
Fast-tracking will allow Nexavar to be available on the market sooner than would normally be the case, and is typically reserved for the deadliest diseases for which few treatment options are available. Cancers of all kinds fall into this category.
As I've said in the past, the cancer market is really heating up right now, and it looks like things are going to continue — it's especially nice to see a second drug making inroads in fighting renal cancer, a area long closed to targeted drug therapies. Because these cancer therapies are effective only in a small percentage of patients, the more options doctors have available, the better it is for those that suffer from cancer.
[tags]Medicine, pharmacy, onyx, bayer, nexavar, liver cancer, cancer, oncology, Pfizer, Temsirolimus, Wyeth[/tags]
No Comments »
No comments yet.
RSS feed for comments on this post.
| TrackBack URI
You can also bookmark
this on del.icio.us or check the cosmos